Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.58 |
| ▸ | RELA | Q04206 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313051 | 0.88 | RAB9A (0.76) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL6773804 | 0.80 | F10 (0.65) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL28764679 | 0.78 | L3MBTL1 (0.66) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL29837506 | 0.78 | L3MBTL1 (0.66) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL6108304 | 0.77 | F10 (0.72) | F10 | |
| SCHEMBL6109802 | 0.76 | SERPINE1 (0.71) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL13923493 | 0.75 | SMN1; SMN2 (0.61) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL6109799 | 0.75 | PPARG (0.63) | F10 | |
| SCHEMBL3618277 | 0.75 | KMT2A (0.55) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL18070988 | 0.75 | L3MBTL1 (0.60) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | claimed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | claimed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| US-6689780-B1 | PYRIDINE DERIVATIVES | ELI LILLY AND COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1140905-B1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1140905-A1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039117-A1 | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | RAB9A 1588/4885SMN1; SMN2 174/4885TP53 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.